A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
← catalyst calendarSponsored by BioNTech SE (industry) · BNTX — their whole pipeline →. With Pfizer.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
2,650actual
Sites
31
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-10 | actual | When the study began enrolling |
| Primary completion | 2025-12-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Influenza
- COVID-19 (Coronavirus Disease 2019)
Interventions
- Biological: Investigational Influenza Vaccine
- Biological: Investigational COVID-19 Vaccine
- Combination product: Investigational Influenza and COVID-19 Combination Vaccine
- Biological: Licensed Influenza Vaccine 1
- Biological: Licensed Influenza Vaccine 2
- Biological: Licensed Influenza Vaccine 3
- Biological: Licensed COVID-19 Vaccine
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting prompted local reactions within 7 days following investigational product administration
measured Day 7
Percentage of participants reporting prompted systemic events within 7 days following investigational product administration
measured Day 7
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
measured 1 month
Percentage of participants reporting serious adverse events (SAEs) through 6 months following investigational product administration
measured 6 months
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed